Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2019 Dec 12;47(4):947–957. doi: 10.1007/s00259-019-04530-1

Fig. 2.

Fig. 2

Changes of SUVmax between baseline and post-therapy in each group. (A-D) 50.0% (10/20), 50.0% (9/18), 75.0% (15/20) and 76.9% (30/39) tumor lesions had decreased SUVmax in group A-D, respectively